vs
Side-by-side financial comparison of Organon & Co. (OGN) and UL Solutions Inc. (ULS). Click either name above to swap in a different company.
Organon & Co. is the larger business by last-quarter revenue ($1.5B vs $340.0M, roughly 4.3× UL Solutions Inc.). On growth, Organon & Co. posted the faster year-over-year revenue change (-3.5% vs -12.4%). Over the past eight quarters, Organon & Co.'s revenue compounded faster (-4.7% CAGR vs -31.8%).
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
The UL enterprise is a global private safety company headquartered in Northbrook, Illinois, composed of three organizations, UL Research Institutes, UL Standards & Engagement and UL Solutions.
OGN vs ULS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.5B | $340.0M |
| Net Profit | $146.0M | — |
| Gross Margin | 53.6% | — |
| Operating Margin | — | 24.4% |
| Net Margin | 10.0% | — |
| Revenue YoY | -3.5% | -12.4% |
| Net Profit YoY | 67.8% | — |
| EPS (diluted) | $0.55 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.5B | $340.0M | ||
| Q4 25 | $1.5B | $789.0M | ||
| Q3 25 | $1.6B | $783.0M | ||
| Q2 25 | $1.6B | $776.0M | ||
| Q1 25 | $1.5B | $705.0M | ||
| Q4 24 | $1.6B | $739.0M | ||
| Q3 24 | $1.6B | $731.0M | ||
| Q2 24 | $1.6B | $730.0M |
| Q1 26 | $146.0M | — | ||
| Q4 25 | $-205.0M | $67.0M | ||
| Q3 25 | $160.0M | $100.0M | ||
| Q2 25 | $145.0M | $91.0M | ||
| Q1 25 | $87.0M | $67.0M | ||
| Q4 24 | $109.0M | $81.0M | ||
| Q3 24 | $359.0M | $88.0M | ||
| Q2 24 | $195.0M | $101.0M |
| Q1 26 | 53.6% | — | ||
| Q4 25 | 49.2% | 49.7% | ||
| Q3 25 | 53.5% | 50.3% | ||
| Q2 25 | 54.8% | 49.4% | ||
| Q1 25 | 55.6% | 48.4% | ||
| Q4 24 | 56.3% | 47.4% | ||
| Q3 24 | 58.3% | 49.0% | ||
| Q2 24 | 58.4% | 50.1% |
| Q1 26 | — | 24.4% | ||
| Q4 25 | -9.8% | 15.0% | ||
| Q3 25 | 15.2% | 19.9% | ||
| Q2 25 | 14.4% | 17.9% | ||
| Q1 25 | 6.7% | 15.5% | ||
| Q4 24 | 8.1% | 15.6% | ||
| Q3 24 | 13.1% | 17.8% | ||
| Q2 24 | 14.6% | 17.3% |
| Q1 26 | 10.0% | — | ||
| Q4 25 | -13.6% | 8.5% | ||
| Q3 25 | 10.0% | 12.8% | ||
| Q2 25 | 9.1% | 11.7% | ||
| Q1 25 | 5.8% | 9.5% | ||
| Q4 24 | 6.8% | 11.0% | ||
| Q3 24 | 22.7% | 12.0% | ||
| Q2 24 | 12.1% | 13.8% |
| Q1 26 | $0.55 | — | ||
| Q4 25 | $-0.78 | $0.33 | ||
| Q3 25 | $0.61 | $0.49 | ||
| Q2 25 | $0.56 | $0.45 | ||
| Q1 25 | $0.33 | $0.33 | ||
| Q4 24 | $0.42 | $0.40 | ||
| Q3 24 | $1.38 | $0.44 | ||
| Q2 24 | $0.75 | $0.50 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OGN
| Established Brands | $880.0M | 60% |
| Women’s Health | $389.0M | 27% |
| Biosimilars | $173.0M | 12% |
ULS
Segment breakdown not available.
